Mild paravalvular regurgitation is not an independent predictor of mortality following TAVI

Similar documents
Paravalvular Regurgitation is a Risk Factor Following TAVI

Comments restricted to Sapien and Corevalve 9/12/2016. Disclosures: Core Lab contracts with Edwards Lifesciences, Middlepeak, Medtronic

Sténose aortique à Bas Débit et Bas Gradient

How to Avoid Prosthesis-Patient Mismatch

Prosthesis-Patient Mismatch or Prosthetic Valve Stenosis?

PARAVALVULAR LEAK POST TAVR. Elements of Follow-up Post TAVR

Strokes After TAVR. Ioannis Iakovou, MD, PhD. Interventional Cardiology Onassis Cardiac Surgery Center

Low Gradient Severe? AS

Transcatheter Aortic Valve Replacement

Strokes After TAVR Reasons for Declining Frequency

Corrado Tamburino, MD, PhD

«Paradoxical» low-flow, low-gradient AS with preserved LV function: A Silent Killer

Low Gradient AS: Multi-Imaging Modalities

TAVR: Review of the Robust Data from Randomized Trials

Federico M Asch MD, FASE MedStar Heart and Vascular Institute Georgetown University Washington, DC

Is Stroke Frequency Declining?

TAVR: Echo Measurements Pre, Post And Intra Procedure

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis

ΔΙΑΔΕΡΜΙΚΗ ΑΝΣΙΚΑΣΑΣΑΗ ΑΟΡΣΙΚΗ ΒΑΛΒΙΔΑ αντιμετώπιση επιπλοκών ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC IICE 2012

Aortic Valve Stenosis: Medical Treatment, Still in the Pipeline?

Post-TAVI Cerebral Embolisms and Potential Protection Means

Low Gradient Severe AS: Who Qualifies for TAVR? Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor

Aortic Stenosis: Background

RANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)

Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients?

PVL Assessment. Is paravalvular regurgitation after TAVR still an important consideration in 2018?

Strokes After TAVR. Incidence (past and present) Multi-factorial Origin

Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

Le TAVI pour tout le monde?

Role of Embolic Protection during TAVR

TAVI Technology and Procedural Changes

How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?

Complications after TAVI: VARC Definitions, Frequency and Management Considerations Patrick W. Serruys, Nicolo Piazza,

Embolic Protection Devices for Transcatheter Aortic Valve Replacement

Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40

TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre

Trans Catheter Aortic Valve Replacement

The Role of TAVI in high-risk and normal-risk Patients

Ioannis Alexanian, MD, PhD Department of Cardiology General Hospital of Chest Diseases Sotiria Athens

Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients

Trans Aortic Valve Replacement Update: 2016 & Beyond

TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR

New imaging modalities for assessment of TAVI procedure and results. R Dulgheru, MD Heart Valve Clinic CHU, Liege

TAVI in Korea, How to Avoid Conduction

Optimal Imaging Technique Prior to TAVI -Echocardiography-

Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI

Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients:

Aortic Valve Replacement Improves Outcome in Patients with Preserved Ejection Fraction: PRO!

Ian T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia

2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR

After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?

Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School

Strokes After TAVR Multi-factorial Origin, Incidence (past and present), and Management Considerations (present and future)

TAVI limitations for low risk patients

Structural Heart Disease Transcatheter Aortic Valve Replacement (TAVR)

Strokes After TAVR: Perspectives from the US CoreValve Trials

Echocardiographic Evaluation of Aortic Valve Prosthesis

TAVR: Intermediate Risk Patients

Vinod H. Thourani, MD, FACC, FACS

TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy

Andrzej Ochala, MD Medical University of Silesia, Katowice, Poland

The best in heart valve disease Aortic valve stenosis

TAVR for low-risk patients in 2017: not so fast.

The Role of Imaging in Transcatheter Aortic Valve Implantation

TAVR IN INTERMEDIATE-RISK PATIENTS

TAVR Cases. Disclosures 2/17/2018. February 17, :15 3:30 PM 15 min

Echocardiographic Evaluation of Aortic Valve Prosthesis

Anti-thrombotic treatment after TAVR: insights from the FRANCE-TAVI Registry

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved

Is Cerebral Embolic Protection Needed for TAVR?

TAVI EN INSUFICIENCIA AORTICA

30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study

TAVI: Transapical Procedures

Complicanze durante TAVI. Brambilla Nedy IRCCS Policlinico San Donato

Case Presentations TAVR: The Good Bad and The Ugly

Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data

TAVR Where are We Going? Victor Guetta, MD FESC FACC The Chaim Sheba Medical Center

LOW RISK TAVR. WHAT THE FUTURE HOLDS

Severe Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative

TAVR in 2020: What is Next!!!!

CoreValve in a Degenerative Surgical Valve

Transcatheter Valve Replacement: Current State in 2017

Diastolic Heart Function: Applying the New Guidelines Case Studies

Imaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013

The Sentinel Dual Filter Device Design Features & EU Clinical Trial Results

Procedural Guidance of TAVR: How to Assure it Goes Right and What to Do If It Doesn t

Current Evidence in TAVI patients using ACURATE and LOTUS valves

DISCLOSURE. Relevant Financial Relationship(s) Off Label Usage. None. None

When Does 3D Echo Make A Difference?

From pacemaker in a donkey to valve disease research in humans

Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients

Patient/prosthesis mismatch: how to evaluate and when to act?

SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes

Disclosures Rebecca T. Hahn, MD, FASE

Aortic Valve Controversies Beyond risk assessment: TAVI for Everybody

Transcription:

Mild paravalvular regurgitation is not an independent predictor of mortality following TAVI Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE Canada Research Chair in Valvular Heart Diseases INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUÉBEC Université LAVAL

Disclosure Statement Grant funding: - Canadian Institutes of Health Research - Heart and Stroke Foundation of Canada Industry: - Edwards Life Science: Research grant Echo Core Lab TAVI - V-Wave Ltd. Research grant Echo Core Lab Heart failure

PVR TAVI

Impact of Paravalvular Regurgitation on 2-Year Outcomes: PARTNER-I A Trial Paravalvular Regurgitation Total (Paravalvular+Central) Regurgitation Kodali et al.; NEJM 2012

1- Is it really mild PVR? 3 Main Questions: 2- Is Mild PVR an actor or a marker? 3- Does mild PVR have a significant and independent impact on survival?

Question #1: Is it really mild PVR?

Quantification of Transcatheter Valve Regurgitation Zoghbi et al. J Am Soc Echocardiogr, 22:975-1014, 2009 Pibarot & Dumesnil, Heart, 98:69-78, 2012

Grading Severity of Paravalvular Regurgitation Bloomfield; JACC Img; 5:441 55, 2012

Multi-window Imaging is Key! SAX LAX 5Ch 3Ch Gonçalves et al. J Am Soc Echocardiogr 2012;25:47-55

Multi-window Imaging is Key! SAX View LAX View Apical 5-Ch View Apical 3-Ch View

Overestimation of Circumferential Extent with Eccentric Jets LAX View SAX View

Overestimation of Circumferential Extent with Eccentric Jets SAX View SAX View

Circumferencial Extent of PVR versus CMR to Assess AR Following TAVR Ribeiro HB, et al. Heart, 2014

Ribeiro HB, et al. Heart, 2014

Multi-View/Multi Parametric TTE versus CMR to Assess AR Following TAVR Ribeiro HB, et al. Heart, 2014

Echo versus CMR to Assess AR Following TAVR Orwat et al. Heart 2014

Question #2: Is Mild PVR Marker or an Actor? Gilbreath C. Opt. Eng. 51(2) March 2012

Predictors of Paravalvular Regurgitation following TAVI Male gender NYHA Class IV Atrial fibrillation AR at baseline MR at baseline Severity and distribution of valve calcification Larger aortic annulus Smaller cover index Inadequate valve positioning Self expending valve Sinning et al. JACC, 2012 Haensig M, EJCTS, 2012 Ewe et al. Am J Cardiol 2011 Ubehaum et al. JACC, 2012 Sinning et al. JACC 2013

Are patients with mild PVR the same as those with none/trace PVR?

Baseline Characteristics of TAVR Patients with Paravalvular Regurgitation in the PARTNER Trial Kodali et al. Eur Heart J 2014

Impact of PVR on Mortality in the PARTNER Trial Kodali et al. Eur Heart J 2014

Question #3: Does Mild PVR have a signifiant impact on survival? Kodali et al.; NEJM 2012

Survival Under Conservative Management After Diagnosis of Native AR Detaint D et al. J Am Coll Cardiol Img 2008;1:1 11

Mild PVR post-savr

Mild PVR post-savr

Impact of Paravalvular Regurgitation on 2-Year Outcomes: PARTNER-I A Trial Paravalvular Regurgitation Total (Paravalvular+Central) Regurgitation Kodali et al.; NEJM 2012

Impact of Moderate-Severe AR on Mortality after TAVI: A Meta-analysis Athapan et al. JACC 2013

Impact of Mild AR on Mortality after TAVI: A Meta-analysis High Heterogeneity (I 2 : 75.28) Sensitivity Analysis: negative results after removing 1 single study Athapan et al. JACC 2013

Impact of AR Post-TAVI / France-2 Registry n= 2769 Van Belle et al. Circulation 2014

Impact AR Post-TAVI / UK Registry Dworakowski R, et al. Heart 2014

Impact of AR on Mortality: Medtronic CoreValve ADVANCE Registry 1,015 patients enrolled from March 2010 to July 2011 in 44 centers 12 countries Linke A et al. TCT 2012

Impact of AR on Mortality CoreValve Pivotal Trial Popma et al. JACC 2014

Impact of AR on Mortality after TAVI: Multicenter Study (1735 Patients) Jerez-Valero et al. J Am Coll Cardiol Intv 2014;7:1022 32

Effect of Acuteness of AR on Mortality After TAVI: Multicenter Study (1735 Patients) Jerez-Valero et al. J Am Coll Cardiol Intv 2014;7:1022 32

Effect of Acuteness of AR on Mortality After TAVI: France 2 Registry Van Belle et al. Circulation 2014

An acute mild PVR could be harmful in patients with small non-compliant LV?

Impact of Balloon Post-dilation on PVR And Outcomes Pre-BPD Post-BPD

Impact of Balloon Post-dilation on PVR And Outcomes PD: 2.5-fold increase in the risk of early cerebrovascular events Nombela-Franco et al. JACC CV Intervention 2012 Nombela-Franco et al. Circulation 2012

Conclusions Moderate/severe PVR occurs in 2-25% of patients and is an independent predictor of mortality Mild PVR is frequent (7-70%) following TAVR The association between mild PVR and increased mortality is in large part related to worse baseline risk profile Mild PVR may have an impact on mortality if: It is underestimated It occurs in a patient with no pre-existing AR and/or restrictive LV physiology

Clinical Implications Current data do not justify additional measures (balloon post-dilation, valve-in-valve, leak closure, SAVR) in patients with mild PVR post-tavi Need to develop Doppler-echo methods to improve quantitation of PVR Need to improve transcatheter heart valves and procedures to minimize/eliminate PVR Optimize Sizing with 3D imaging of annulus Balloon post-dilation, V-inV New valve models with better sealing